

Ajdovščina, Slovenia, October 13, 2023

Sartorius initiates construction of Ajdovščina campus in Slovenia

- Establishment of the campus within the next ten years
- Inauguration ceremony of a new building and 25th anniversary celebration
- Production of sterile chromatography columns used in cell and gene therapy at the Ajdovščina site

The life science group Sartorius has announced its long-term plans to expand its existing site in Ajdovščina into a campus within the next ten years. Approximately 200 new skilled positions could be created, according to the concept. The future campus in Ajdovščina is projected to have a total area of around 30,000 square meters and will be a multifunctional complex comprising facilities for production, research, and education. Designed to be sustainable, the campus will include a solar power plant and technologies to recycle by-products for heating and water reuse.

The plans were unveiled at the 25th anniversary celebration of BIA Separations, which Sartorius acquired in 2020. During the ceremony, Sartorius also inaugurated new premises at its existing site. The investment of approximately 9 million euros in an adjacent building will add 4,500 square meters to the existing area, which is currently 8,800 square meters. Commissioning of the new building is scheduled for early 2024 and will mark the start of the development of the campus.

"The new building and the campus will enable us to meet our customers' future needs for technologies to produce new modalities. We are committed to further enhance our innovation activities and to expand our offering for the manufacturing of gene therapies and other advanced therapies," said René Fáber, Head of Bioprocess Solutions Division and Member of the Executive Board of Sartorius.

With approximately 230 employees at the Ajdovščina site, Sartorius develops and manufactures market-leading products for the purification and analysis of large biomolecules, such as viruses, plasmids, and mRNA, which are used in vaccines as well as in cell and gene therapies and other advanced therapies.

A profile of Sartorius

Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications and vaccines safely, rapidly and economically. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius delivers significant organic growth and

regularly expands its portfolio through the acquisition of complementary technologies. In 2022, the company generated sales revenue of around 4.2 billion euros. Currently, around 15,000 employees are working for customers around the globe.

Press Contact

Contact Timo Lindemann

Corporate Communications

+49 (0)551 308 4724 timo.lindemann@sartorius.com

Follow Sartorius on X (Twitter) [@Sartorius Group](#) and on [LinkedIn](#).